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Sameer Gafoor, MD, Jennifer Franke, MD, Horst Sievert, MD, PHDR enal artery stenosis (RAS) occurs in up to5% of people with hypertension and isassociated with ischemic nephropathy and
other complications. It has been hypothesized that
RAS is a potentially reversible cause of hyperten-
sion and these other sequelae, and the practice
of renal artery stenting has grown to meet this
perceived need. However, data from randomized
controlled trials is somewhat equivocal, demon-
strating little response in blood pressure or kidney
function following stenting. Such trials have led to
a spirited debate as to the quality and robustness
of the data.SEE PAGE 2487In this issue of the Journal, Murphy et al. (1)
discuss data from high-risk subsets of the CORAL
(Cardiovascular Outcomes in Renal Atherosclerotic
Lesions) trial (2), which included 947 patients with
RAS randomized to stent placement plus medical
therapy or to medical therapy alone. These patient
subsets had high-grade stenoses at baseline, higher
intra-arterial pressure gradients, and higher baseline
blood pressure. The authors found no difference
or signiﬁcant treatment effect from stenting. We*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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Many have criticized the CORAL trial. One criticism
is that “severe” renal lesions were not enrolled and
were stented outside the trial because of patient or
physician preference; likewise “mild” renal lesions
were not enrolled and were sent to medical therapy.
Therefore many lesions included in the trial were
actually nonobstructive and of intermediate severity.
To the authors’ credit, the CORAL trial has listed
reasons for screening failures in the appendix
showing that a higher degree of stenosis severity was
not a reason for patient exclusion. However, critics
respond that the “selection” happened before a pa-
tient was even considered for the study, an assertion
that is hard to prove or disprove. Another criticism is
that 2-dimensional angiography was used to select
functional severity, without hemodynamic assess-
ment. White, in a recent editorial published in JACC:
Cardiovascular Interventions after publication of the
CORAL trial (3), poses 2 remaining questions: 1) Does
renal revascularization with stenting plus medical
therapy offer an effective treatment for RAS in
patients whose blood pressure remains uncontrolled
despite multifactorial medical therapy?; and 2) What
is the beneﬁt of renal artery stenting plus medial
therapy for RAS that is conﬁrmed hemodynamically
and not just by angiography?
Murphy et al. (1) attempt to address those 2 ques-
tions, but there are even more basic issues of trial
design to address. There was no period of repeated
blood pressure measurements prior to enrollment.
Although this was true for both groups, this never-
theless introduces more statistical “noise,” as this
may have caused more patients with spuriously high
blood pressure or “white-coat” hypertension to be
included in the study. Furthermore, the number of
medications increased in both groups (stenting þ
“OMT” [optimized medical therapy] vs. “OMT”) from
2.1  1.6 at baseline to 3.3  1.5 and 3.5  1.4 medi-
cations, respectively. The increase in medications
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ferences were attributable to stenting.
Whether RAS is the cause of hypertension is a
much larger question than ﬁnding out whether RAS is
“signiﬁcant.” If RAS is a reversible cause of a patient’s
hypertension, then stenting may be helpful whether
the blood pressure is uncontrolled. If RAS is not a
reversible cause of a patient’s hypertension, then
stenting even a severe lesion will not be helpful
regarding blood pressure control. Stenting may be a
better treatment option than taking life-long medi-
cations in cases where a stenosis is the cause of hy-
pertension, because it is a 1-time intervention, unlike
medications that have compliance and side effect is-
sues that are relevant in clinical and especially in
real-world settings.
As for the question of hemodynamic beneﬁt: If we
assume that stenosis severity is the main driver of the
effect of RAS on hypertension, then the method by
which the stenosis is measured is important. The
CORAL trial required a $60% stenosis, which the
authors argue was a common threshold in use at that
time and would therefore reﬂect general practice.
Anatomic stenosis is also variable, with angiographic
stenosis often not matching actual stenosis. The ma-
jority of RAS is due to ostial stenosis, which is
sometimes difﬁcult to visualize in a standardized
fashion on angiography. Pressure gradient assess-
ment in the study required the on-site investigator’s
assessment of stenosis severity as $60% or <80%,
and was considered “positive” if the gradient
was $20 mm Hg. Even in those patients, however,
this was not always strictly followed. Figure 1 in
Murphy et al. (1) shows 230 patients in the stent group
and 208 in the medical therapy group with 60% to
80% stenosis, but pressure gradients were only
measured in 121 patients in the stent group and 78 in
the medical therapy group (53% and 34%, respec-
tively). When mean gradients are used, the numbers
are even worse (113 and 70 patients, or 49% and 34%,
respectively). How reliable are the data when one-half
or fewer of patients underwent the indicated addi-
tional gradient measurement? This lends credence to
the concern that less severe stenoses were addressed
by the trial, which is biased in favor ofmedical therapy.
In addition, pressure gradients of at least 20 mm Hg
alonemaynot be the best indicator for stenting. Should
a higher gradient be used as the cutoff for enrollment?
Why not 40 or 50 mm Hg? Murphy et al. (1) point out
that higher gradients “seem” to be pushing toward
medical therapy; however, patients with even higher
gradients or stenoses were the ones most likely to be
excluded from the study by physicians. In addition,
other studies point to functional testing withdopamine as having an additional beneﬁt and a greater
area under the receiver-operating characteristic curve
for these patients, and may therefore be the preferred
test in questionable subsets (4–6). Renal fractional
ﬂow reserve is another potential functional study (7)
that may be helpful.
From a statistical standpoint, there are issues with
analyzing subgroups from a trial. The authors point
out that subgroup tests are underpowered. Of note,
only 18% of patients were originally randomized from
the 5,322 patients deemed suitable—raising the
question of validity of subgroup analysis from this
cohort. The appendix from the original CORAL article
goes through the reasons for not enrolling in 4,375
patients, including 34.5% where RAS was <60%, and
23% for whom study exclusion was for either patient
or physician preference. The high number of exclu-
sions for patient or physician preference reﬂects the
fact that 1 of 5 patients were excluded because
randomization was not preferred, a potential source
of bias.
Murphy et al. (1) do not analyze the speciﬁc clinical
situations where renal stenting may have been
beneﬁcial. Those include patients with severe hy-
pertension, advanced chronic kidney disease, or more
rapid decrease in renal function, as well as those with
severe bilateral RAS or severe unilateral stenosis in a
patient with solitary kidney. These clinical groups
may beneﬁt from stenting, but were not included in
this trial. The door to renal stenting is not closed yet.
Meta-analyses including the CORAL trial have
shown some beneﬁt of renal artery stenting. These
include the 7-study report by Caielli et al. (8), which
showed a decrease in diastolic blood pressure and
less need for antihypertensive drugs following
stenting. This was also shown in the 8-study meta-
analysis by Bavry et al. (9), demonstrating a reduc-
tion in the number of antihypertensive medications
required at follow-up.
We commend the authors for publishing this paper
and ﬁndings, which were part of the critique from the
original CORAL trial publication. Although this paper
explores some of the critical questions left over by
publication of the CORAL trial, there are enough is-
sues with the main CORAL trial enrollment and trial
design to make the results of this paper susceptible to
similar criticisms.
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